Ross Osborn
Stock Analyst at Cantor Fitzgerald
(1.95)
# 3,138
Out of 5,154 analysts
119
Total ratings
30.28%
Success rate
-4%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVRX CVRx, Inc. | Maintains: Overweight | $11 → $13 | $8.25 | +57.58% | 4 | Nov 6, 2025 | |
| PRE Prenetics Global | Maintains: Overweight | $26 → $32 | $17.80 | +79.78% | 8 | Oct 29, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Overweight | $7 → $9 | $2.79 | +222.58% | 4 | Aug 8, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Neutral | $92 → $95 | $107.39 | -11.54% | 2 | Aug 6, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $13.83 | +80.77% | 10 | Aug 5, 2025 | |
| MDXG MiMedx Group | Maintains: Overweight | $11 → $12 | $4.50 | +166.67% | 5 | Jul 31, 2025 | |
| BVS Bioventus | Initiates: Overweight | $12 | $8.41 | +42.69% | 1 | Jul 7, 2025 | |
| XGN Exagen | Maintains: Overweight | $8 → $7 | $3.29 | +112.77% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.40 | +42.86% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $14.03 | +21.17% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $2.70 | +233.33% | 11 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $46 | $18.87 | +143.77% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $1.09 | +633.94% | 10 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $28.55 | -15.94% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.93 | +107.25% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $6.20 | +45.16% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $4.75 | +342.11% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $3.74 | +327.81% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.38 | +153.62% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.20 | +1,161.99% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $0.83 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $258 | $10.42 | +2,378.89% | 2 | Aug 18, 2023 |
CVRx, Inc.
Nov 6, 2025
Maintains: Overweight
Price Target: $11 → $13
Current: $8.25
Upside: +57.58%
Prenetics Global
Oct 29, 2025
Maintains: Overweight
Price Target: $26 → $32
Current: $17.80
Upside: +79.78%
Organogenesis Holdings
Aug 8, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $2.79
Upside: +222.58%
LeMaitre Vascular
Aug 6, 2025
Maintains: Neutral
Price Target: $92 → $95
Current: $107.39
Upside: -11.54%
SI-BONE
Aug 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $13.83
Upside: +80.77%
MiMedx Group
Jul 31, 2025
Maintains: Overweight
Price Target: $11 → $12
Current: $4.50
Upside: +166.67%
Bioventus
Jul 7, 2025
Initiates: Overweight
Price Target: $12
Current: $8.41
Upside: +42.69%
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $3.29
Upside: +112.77%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.40
Upside: +42.86%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $14.03
Upside: +21.17%
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $2.70
Upside: +233.33%
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $18.87
Upside: +143.77%
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $1.09
Upside: +633.94%
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $28.55
Upside: -15.94%
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $1.93
Upside: +107.25%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $6.20
Upside: +45.16%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $4.75
Upside: +342.11%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $3.74
Upside: +327.81%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.38
Upside: +153.62%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.20
Upside: +1,161.99%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.83
Upside: -
Aug 18, 2023
Reiterates: Neutral
Price Target: $258
Current: $10.42
Upside: +2,378.89%